|
|
|
|
|
|
|
HIGHLIGHTS FROM THE 2024 AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING |
|
|
|
|
|
AUA-IBCG Bladder Cancer Forum
|
|
| Role of Urinary Markers in Surveillance of NMIBC Patients
|
| Kamal Pohar, MD, and Kelly Bree, MD
|
| In this AUA-IBCG Bladder Cancer Forum Yair Lotan moderated a discussion with Kamal Pohar and Kelly Bree discussing the role of urinary markers in surveillance of NMIBC patients. |
|
|
|
|
|
| Optimal TURBT: Do Skilled Urologists Really Need to Perform reTUR for all HG Patients?
|
| Jeremy Teoh, MBBS, FRCSEd, FCSHK, FHKAM, and Badrinath Konety, MD
|
| In this AUA-IBCG Bladder Cancer Forum Neal Shore moderated a discussion with Jeremy Teoh and Badrinath Konety debating whether skilled urologists truly need to perform re-TUR for all high-grade bladder cancer patients. |
|
|
|
|
|
| Management of Recurrent Low-Grade Intermediate Risk Bladder Tumors |
| Sarah Psutka, MD, MS, Paramananthan Mariappan, MD |
| In this AUA-IBCG Bladder Cancer Forum Robert Svatek moderated a discussion with Sarah Psutka and Paramananthan Mariappan discussing the management of recurrent low-grade intermediate-risk bladder tumors. |
|
|
|
|
|
|
|
|
|
|
| Very High-Risk NMIBC with Variant Histology
|
| Michael Cookson, MD, and Paolo Gontero, MD
|
| In this AUA-IBCG Bladder Cancer Forum Juan Palou moderated a discussion with Paulo Gontero, and Michael Cookson discussin the management of very high-risk non-muscle invasive bladder cancer with variant histology. |
|
|
|
|
|
| BCG Unresponsive Disease: How Much Risk Can My Patient Tolerate?
|
| Sima Porten, MD, MPH and Roger Li, MD
|
| In this AUA-IBCG Bladder Cancer Forum, Alexandre Zlotta moderated a discussion with Sima Porten and Roger Li discuss how much risk patients can tolerate in the BCG unresponsive disease space.
|
|
|
|
|
|
| Can we Settle the Debate on PLND in Radical Cystectomy?
|
| Seth Lerner, MD, and Sia Daneshmand, MD
|
| In this AUA-IBCG Bladder Cancer Forum, John Taylor moderated a discussion with Sia Daneshmand and Seth Lerner discussing the optimal management of pelvic lymph node dissection for patients during radical cystectomy.
|
|
|
|
|
|
| Can I use Markers and Imaging to Avoid Local Consolidation for Patient who has cT0 stage after Neoadjuvant Chemo or IO? |
| Stephen Williams, MD, MBA, MS, FACS, FACHE, and Petros Grivas, MD, PhD
|
| In this AUA-IBCG Bladder Cancer Forum, Arnulf Stenzl moderated a discussion with Stephen Williams and Petros Grivas on whether biomarkers and imaging can be used to avoid local consolidation for patients who are cT0 after neoadjuvant chemo-or-immunotherapy (IO).
|
|
|
|
|
|
| First Line Therapy for Locally Advanced/Metastatic UC in 2024
|
| Chiara Mercinelli, MD, Shilpa Gupta, MD, and Karima Oualla, MD, MSc
|
| In this AUA-IBCG Bladder Cancer Forum, Chiara Mercinelli moderated a discussion with Shilpa Gupta, and Karima Oualla discussing the first-line therapy for locally advanced or metastatic urothelial carcinoma in 2024.
|
|
|
|
|
|
|
|
|
|
|
